|
Mr. Perry has served as our Chief Financial Officer and Executive Vice President since January 2007. Prior to joining Elixir, Mr. Perry served as Chief Financial Officer of Domantis, Ltd., a biopharmaceutical company that was recently acquired by GlaxoSmithKline, which he joined in June 2006. From May 2003 to August 2005, Mr. Perry served as Senior Vice President and Chief Financial Officer at Transkaryotic Therapies. At Domantis and Transkaryotic Therapies, Mr. Perry was responsible for overseeing all aspects of accounting, finance, planning, taxation and investor relations. Prior to Transkaryotic Therapies, Mr. Perry served as Senior Vice President, Finance and Business Development, Life Sciences at PerkinElmer Inc. where he was responsible for their financial operations. Mr. Perry holds a B.A. from Amherst College. | 